1
© 2003 Nature Publishing Group HIGHLIGHTS NATURE REVIEWS | IMMUNOLOGY VOLUME 3 | SEPTEMBER 2003 | 695 Viruses are always striving to outwit their host, and staying one step ahead is proving difficult in our fight against HIV-1. The expression of inhibitors, known as restriction factors, by humans and nonhuman primates provides an innate mechanism that confers resistance to infection with various retroviruses. However, it seems that HIV-1 can hijack a host protein to counteract the inhibition of virus replication mediated by these factors. Reporting in Nature Medicine, Towers et al. show that the interaction between HIV-1 capsid protein (CA) and the host cell protein cyclophilin A (CYPA) modulates the sensitivity of HIV-1 to host restriction factors. The CYPA binding site in CA is positioned close to residues that are involved in recognition by restriction factors. So, the authors investigated how the interaction between CA and CYPA influences the sensitivity of HIV-1 to restriction factors. Disruption of the CYPACA interaction either by mutating the CYPA binding site in HIV-1 CA or by treating the target cells with cyclosporin A (CsA), which effectively competes for the binding of CYPA, had different effects on HIV-1 infectivity depending on the species of the target cell. In human cells, inhibition of the CYPACA interaction reduced the infectivity of HIV-1, as HIV-1 became sensitive to the restriction factor REF1. By contrast, efficient infection of owl monkey (OMK) cells occurred when the CYPACA interaction was prevented, indicating that this binding event is required for restriction by OMK cells. Therefore, it seems that specific adaptation of HIV-1 in human cells, but not unnatural hosts, has allowed HIV-1 to avoid recognition by restriction factors and override innate antiviral safety measures. Lucy Bird References and links ORIGINAL RESEARCH PAPER Towers, G. J. et al. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nature Med. 3 August 2003 (DOI: 10.1038/nm910) Overriding safety measures HIV IN BRIEF AID mutant analyses indicate requirement for class-switch-specific cofactors. Ta, V.-T. et al . Nature Immunol . 10 August 2003 (DOI: 10.1038/ni964) Activation-induced cytidine deaminase (AID) is known to be the only B-cell-specific factor required for both class-switch recombination (CSR) and somatic hypermutation (SHM) during the maturation of an antibody response. How then does AID differentially regulate these two processes? Honjo and colleagues show that this might be achieved by specific cofactors that regulate substrate interaction. Point mutations in the carboxy- terminal domain of AID abrogated CSR but did not affect SHM, which indicates the involvement of a CSR-specific cofactor that binds to the carboxyl terminus of AID. The nonimmunoglobulin portion of λ5 mediates cell-autonomous pre-B cell receptor signaling. Ohnishi, K. & Melchers, F. Nature Immunol . 3 August 2003 (DOI: 10.1038/ni959) Expression of the pre-BCR — composed of one rearranged heavy chain and a surrogate light chain (SLC; which is itself composed of VpreB and λ5) — is a crucial intermediate step in B-cell development, allowing B cells to proliferate in a ligand-independent manner. Deletion or mutation of the amino-terminal non- immunoglobulin region of λ5 led to increased cell-surface expression of the pre-BCR, but decreased pre-BCR aggregation and decreased phosphorylation of proteins in the pre-BCR complex. These results indicate that the amino-terminal region of λ5 is required for signal transduction by the pre-BCR in response to receptor crosslinking. No ligands or other cell types were added to the pre-B cells, so the authors propose that this crosslinking involves a linking factor produced by the pre-B cell itself or non-covalent interactions between two λ5 non-immunoglobulin regions. Cutting edge: the B cell chemokine CXC chemokine ligand 13/B lymphocyte chemoattractant is expressed in the high endothelial venules of lymph nodes and Peyer’s patches and affects B cell trafficking across high endothelial venules. Ebisuno, Y. et al. J. Immunol. 171, 1642–1646 (2003) The chemokines CC-chemokine ligand 21 (CCL21) and CCL19 are localized to high endothelial venules (HEVs) and are involved in controlling T-cell trafficking to lymph nodes or Peyer’s patches. In this study, Ebisuno et al. analysed the role of the B-cell chemoattractant CXCL13 in the trafficking of B cells across HEVs. CXCL13 was found to be expressed on the luminal surface of HEVs. B-cell arrest in HEVs of Peyer’s patches was impaired in CXCL13- deficient mice, but superfusion of the Peyer’s patches with CXCL13 restored the expression of CXCL13 at the luminal surface and some B cells were once again able to adhere. This study shows that CXCL13 expressed by HEVs has a role in the trafficking of B cells in lymphoid organs. LYMPHOCYTE MIGRATION B-CELL DEVELOPMENT ANTIBODY RESPONSES

Hiv: Overriding safety measures

  • View
    227

  • Download
    4

Embed Size (px)

Citation preview

Page 1: Hiv: Overriding safety measures

© 2003 Nature Publishing Group

H I G H L I G H T S

NATURE REVIEWS | IMMUNOLOGY VOLUME 3 | SEPTEMBER 2003 | 695

Viruses are always striving to outwittheir host, and staying one stepahead is proving difficult in ourfight against HIV-1. The expressionof inhibitors, known as restrictionfactors, by humans and nonhumanprimates provides an innatemechanism that confers resistanceto infection with variousretroviruses. However, it seems thatHIV-1 can hijack a host protein tocounteract the inhibition of virusreplication mediated by thesefactors. Reporting in NatureMedicine, Towers et al. show thatthe interaction between HIV-1capsid protein (CA) and the hostcell protein cyclophilin A (CYPA)modulates the sensitivity of HIV-1to host restriction factors.

The CYPA binding site in CA ispositioned close to residues that areinvolved in recognition byrestriction factors. So, the authorsinvestigated how the interactionbetween CA and CYPA influencesthe sensitivity of HIV-1 torestriction factors. Disruption ofthe CYPA−CA interaction either by

mutating the CYPA binding site inHIV-1 CA or by treating the targetcells with cyclosporin A (CsA),which effectively competes for the binding of CYPA, had differenteffects on HIV-1 infectivitydepending on the species of thetarget cell. In human cells, inhibitionof the CYPA−CA interactionreduced the infectivity of HIV-1,as HIV-1 became sensitive to therestriction factor REF1. By contrast,efficient infection of owl monkey(OMK) cells occurred when theCYPA−CA interaction wasprevented, indicating that thisbinding event is required forrestriction by OMK cells.

Therefore, it seems that specificadaptation of HIV-1 in humancells, but not unnatural hosts, hasallowed HIV-1 to avoid recognitionby restriction factors and overrideinnate antiviral safety measures.

Lucy Bird

References and linksORIGINAL RESEARCH PAPER Towers, G. J.et al. Cyclophilin A modulates the sensitivity ofHIV-1 to host restriction factors. Nature Med. 3 August 2003 (DOI: 10.1038/nm910)

Overriding safetymeasures

H I V IN BRIEF

AID mutant analyses indicate requirement for class-switch-specific cofactors.Ta, V.-T. et al. Nature Immunol. 10 August 2003 (DOI: 10.1038/ni964)

Activation-induced cytidine deaminase (AID) is known to be the only B-cell-specific factor required for both class-switchrecombination (CSR) and somatic hypermutation (SHM) duringthe maturation of an antibody response. How then does AIDdifferentially regulate these two processes? Honjo and colleaguesshow that this might be achieved by specific cofactors thatregulate substrate interaction. Point mutations in the carboxy-terminal domain of AID abrogated CSR but did not affect SHM,which indicates the involvement of a CSR-specific cofactor thatbinds to the carboxyl terminus of AID.

The nonimmunoglobulin portion of λ5 mediates cell-autonomous pre-B cell receptor signaling.Ohnishi, K. & Melchers, F. Nature Immunol. 3 August 2003 (DOI: 10.1038/ni959)

Expression of the pre-BCR — composed of one rearranged heavychain and a surrogate light chain (SLC; which is itself composedof VpreB and λ5) — is a crucial intermediate step in B-celldevelopment, allowing B cells to proliferate in a ligand-independentmanner. Deletion or mutation of the amino-terminal non-immunoglobulin region of λ5 led to increased cell-surfaceexpression of the pre-BCR, but decreased pre-BCR aggregation anddecreased phosphorylation of proteins in the pre-BCR complex.These results indicate that the amino-terminal region of λ5 isrequired for signal transduction by the pre-BCR in response toreceptor crosslinking. No ligands or other cell types were added tothe pre-B cells, so the authors propose that this crosslinking involvesa linking factor produced by the pre-B cell itself or non-covalentinteractions between two λ5 non-immunoglobulin regions.

Cutting edge: the B cell chemokine CXC chemokineligand 13/B lymphocyte chemoattractant is expressedin the high endothelial venules of lymph nodes andPeyer’s patches and affects B cell trafficking acrosshigh endothelial venules.Ebisuno, Y. et al. J. Immunol. 171, 1642–1646 (2003)

The chemokines CC-chemokine ligand 21 (CCL21) and CCL19are localized to high endothelial venules (HEVs) and are involvedin controlling T-cell trafficking to lymph nodes or Peyer’spatches. In this study, Ebisuno et al. analysed the role of the B-cellchemoattractant CXCL13 in the trafficking of B cells across HEVs.CXCL13 was found to be expressed on the luminal surface of HEVs.B-cell arrest in HEVs of Peyer’s patches was impaired in CXCL13-deficient mice, but superfusion of the Peyer’s patches with CXCL13restored the expression of CXCL13 at the luminal surface and someB cells were once again able to adhere. This study shows thatCXCL13 expressed by HEVs has a role in the trafficking of B cells in lymphoid organs.

LY M P H O C Y T E M I G R AT I O N

B - C E L L D E V E LO P M E N T

A N T I B O DY R E S P O N S E S